Payment overview · 2025
General Payments
$1,655.32
18 reported records · 9 companies
Healthcare provider profile · identity verified
Kurtis Jon Melin, MD
Allopathic & Osteopathic Physicians|Family Medicine · SPARTANBURG, SC · NPI 1467749929
Verified facts
What the public records show
CMS Open Payments records show Kurtis Jon Melin, MD received $1,655.32 in general payments during 2025 across 18 reported records.
AstraZeneca Pharmaceuticals LP accounted for 36.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1183 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $605.50 | 36.6% | 6 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $329.57 | 19.9% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $125.09 | 7.6% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $118.41 | 7.2% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $116.42 | 7.0% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $108.10 | 6.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $103.84 | 6.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $101.10 | 6.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $47.29 | 2.9% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,655.32 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $285.96 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $245.82 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $172.38 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $121.49 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $118.41 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $116.42 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $108.10 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $105.96 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $103.84 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $101.10 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $92.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
185 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
120 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
73 | 73 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1183 | 55 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2347 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 2198 | 95 |
| Amlodipine Besylate | Amlodipine Besylate | 1881 | 89 |
| Sertraline Hcl | Sertraline Hcl | 1292 | 55 |
| Omeprazole | Omeprazole | 1276 | 52 |
| Gabapentin | Gabapentin | 1266 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1246 | 70 |
| Divalproex Sodium | Divalproex Sodium | 1221 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 1200 | 56 |
| Eliquis | Apixaban | 1183 | 55 |
| Potassium Chloride | Potassium Chloride | 1070 | 72 |
| Escitalopram Oxalate | Escitalopram Oxalate | 1012 | 37 |
| Furosemide | Furosemide | 878 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 812 | 44 |
| Lisinopril | Lisinopril | 805 | 41 |
| Trazodone Hcl | Trazodone Hcl | 759 | 42 |
| Memantine Hcl | Memantine Hcl | 703 | 32 |
| Losartan Potassium | Losartan Potassium | 698 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 668 | 33 |
| Donepezil Hcl | Donepezil Hcl | 643 | 28 |
| Carvedilol | Carvedilol | 642 | 36 |
| Mirtazapine | Mirtazapine | 619 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 590 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 554 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 509 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 459 | 30 |
| Levetiracetam | Levetiracetam | 452 | 16 |
| Midodrine Hcl | Midodrine Hcl | 439 | 21 |
| Metformin Hcl | Metformin Hcl | 438 | 24 |
| Allopurinol | Allopurinol | 437 | 19 |
| Buspirone Hcl | Buspirone Hcl | 417 | 19 |
| Montelukast Sodium | Montelukast Sodium | 389 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 360 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 345 | 18 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 326 | 14 |
| Spironolactone | Spironolactone | 323 | 18 |
| Risperidone | Risperidone | 322 | 14 |
| Simvastatin | Simvastatin | 301 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 297 | 17 |
| Amiodarone Hcl | Amiodarone Hcl | 271 | suppressed |
| Tradjenta | Linagliptin | 215 | suppressed |
| Bumetanide | Bumetanide | 205 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 204 | 12 |
| Xarelto | Rivaroxaban | 201 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 199 | 12 |
| Famotidine | Famotidine | 189 | 16 |
| Farxiga | Dapagliflozin Propanediol | 185 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 181 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 175 | 15 |
| Baclofen | Baclofen | 144 | suppressed |
| Finasteride | Finasteride | 135 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 127 | suppressed |
| Digoxin | Digoxin | 124 | suppressed |
| Lovastatin | Lovastatin | 124 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 121 | 15 |
| Olanzapine | Olanzapine | 121 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 120 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 117 | suppressed |
| Celecoxib | Celecoxib | 114 | suppressed |
| Nystatin | Nystatin | 110 | 37 |
| Jardiance | Empagliflozin | 109 | suppressed |
| Glipizide | Glipizide | 107 | suppressed |
| Methimazole | Methimazole | 106 | suppressed |
| Sucralfate | Sucralfate | 105 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 102 | suppressed |
| Fenofibrate | Fenofibrate | 100 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 95 | suppressed |
| Lorazepam | Lorazepam | 95 | 28 |
| Atenolol | Atenolol | 94 | suppressed |
| Entresto | Sacubitril/Valsartan | 92 | suppressed |
| Gemtesa | Vibegron | 92 | suppressed |
| Januvia | Sitagliptin Phosphate | 88 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 88 | suppressed |
| Ezetimibe | Ezetimibe | 87 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 87 | 23 |
| Latanoprost | Latanoprost | 87 | 17 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 84 | 24 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 83 | 82 |
| Paroxetine Hcl | Paroxetine Hcl | 82 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 80 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 78 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 77 | 14 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 75 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 73 | 73 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 73 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 73 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 73 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 73 | suppressed |
| Ondansetron Odt | Ondansetron | 72 | 23 |
| Tramadol Hcl | Tramadol Hcl | 71 | 17 |
| Topiramate | Topiramate | 70 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 31 |
| Breo Ellipta | Fluticasone/Vilanterol | 67 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 67 | suppressed |
| Myrbetriq | Mirabegron | 67 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | suppressed |
| Brilinta | Ticagrelor | 65 | suppressed |
| Glipizide Er | Glipizide | 64 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 63 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 61 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 61 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 59 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 59 | suppressed |
| Insulin Lispro | Insulin Lispro | 59 | suppressed |
| Prednisone | Prednisone | 59 | 27 |
| Metformin Hcl Er | Metformin Hcl | 58 | suppressed |
| Valsartan | Valsartan | 57 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 55 | suppressed |
| Chlorthalidone | Chlorthalidone | 54 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 54 | 13 |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 53 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | suppressed |
| Pramipexole Er | Pramipexole Di-Hcl | 53 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 52 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 52 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 52 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 52 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 52 | suppressed |
| Lubiprostone | Lubiprostone | 52 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 52 | suppressed |
| Primidone | Primidone | 52 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 52 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 52 | 15 |
| Zafirlukast | Zafirlukast | 52 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 51 | suppressed |
| Pregabalin | Pregabalin | 50 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 48 | 17 |
| Glimepiride | Glimepiride | 46 | suppressed |
| Cephalexin | Cephalexin | 45 | 36 |
| Trulicity | Dulaglutide | 42 | suppressed |
| Xifaxan | Rifaximin | 42 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | suppressed |
| Rexulti | Brexpiprazole | 41 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 40 | 23 |
| Cilostazol | Cilostazol | 40 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 40 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 37 | 18 |
| Nystop | Nystatin | 37 | 21 |
| Budesonide Ec | Budesonide | 36 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 36 | suppressed |
| Fluconazole | Fluconazole | 35 | 23 |
| Budesonide Dr | Budesonide | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 17 |
| Prazosin Hcl | Prazosin Hcl | 34 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 33 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 33 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 32 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 18 |
| Ketoconazole | Ketoconazole | 31 | 19 |
| Insulin Aspart Flexpen | Insulin Aspart | 29 | suppressed |
| Klor-Con 10 | Potassium Chloride | 29 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 13 |
| Benztropine Mesylate | Benztropine Mesylate | 28 | suppressed |
| Roflumilast | Roflumilast | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Calcium Acetate | Calcium Acetate | 24 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 24 | 12 |
| Dapagliflozin | Dapagliflozin Propanediol | 22 | suppressed |
| Estradiol | Estradiol | 22 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 17 |
| Rasagiline Mesylate | Rasagiline Mesylate | 22 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 21 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 12 |
| Haloperidol Lactate | Haloperidol Lactate | 19 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 19 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Phenazopyridine Hcl | Phenazopyridine Hcl | 19 | suppressed |
| Verapamil Sr | Verapamil Hcl | 19 | suppressed |
| Budesonide | Budesonide | 18 | suppressed |
| Darifenacin Er | Darifenacin Hydrobromide | 18 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 18 | suppressed |
| Restasis | Cyclosporine | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 15 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 14 | suppressed |
| Cyclosporine | Cyclosporine | 14 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Mirabegron Er | Mirabegron | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Sulfasalazine | Sulfasalazine | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Trospium Chloride | Trospium Chloride | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | 12 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Neupro | Rotigotine | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,655.32 · 18 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Brinsupri, FASENRA, INGREZZA, Ohtuvayre, PREVNAR 20, REXULTI, TEZSPIRE, Tymlos, VRAYLAR | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error